InVivo wins FDA nod for new pivotal trial of its neuro-spinal scaffold
The objective performance criterion for he study had been a 25% AIS conversion rate, InVivo said.
The post InVivo wins FDA nod for new pivotal trial of its neuro-spinal scaffold appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Food & Drug Administration (FDA) Neurological Regulatory/Compliance Spinal InVivo Therapeutics Source Type: news